Compare NBHC & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | INVA |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2012 | 2004 |
| Metric | NBHC | INVA |
|---|---|---|
| Price | $41.58 | $22.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $45.33 | $36.80 |
| AVG Volume (30 Days) | 495.8K | ★ 746.7K |
| Earning Date | 01-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | ★ 2.85 | 1.52 |
| Revenue | ★ $398,271,000.00 | $388,521,000.00 |
| Revenue This Year | $39.99 | $13.23 |
| Revenue Next Year | $6.69 | $8.58 |
| P/E Ratio | ★ $14.68 | $14.89 |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $32.83 | $16.52 |
| 52 Week High | $43.54 | $23.42 |
| Indicator | NBHC | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 79.17 |
| Support Level | $39.95 | $21.55 |
| Resistance Level | $42.45 | $23.42 |
| Average True Range (ATR) | 1.23 | 0.67 |
| MACD | -0.00 | 0.24 |
| Stochastic Oscillator | 73.50 | 81.77 |
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.